MEDIA

Caregiver Profile

Caregiver Profile

Meet Dr. Paul A. Rufo

EDUCATION

Undergraduate Degree

  • Harvard College , 1985 , Boston , MA

Medical School

  • University of Massachusetts Medical School , 1990 , Worcester , MA

Internship

  • Johns Hopkins Hospital , 1991 , Baltimore , MD

Residency

  • Johns Hopkins Hospital , 1993 , Baltimore , MD

Fellowship

Pediatric Gastroenterology
  • Boston Children's Hospital , 1994 , Boston , MA

Fellowship

Cell Biology
  • Boston Children's Hospital , 1996 , Boston , MA

Fellowship

Pfizer Fellowship in Clinical Investigation
  • Beth Israel Deaconess Medical Center , 2002 , Boston , MA

PROFESSIONAL HISTORY

Assistant Professor of Pediatrics at HMS.  I also serve as Program Director for the HMS Fellowship in Pediatric Gastroenterology and Nutrition.

CERTIFICATIONS

  • American Board of Pediatrics, Pediatric Gastroenterology
  • Safe Zone Trained

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Analysis of Using the Total White Blood Cell Count to Define Severe New-onset Ulcerative Colitis in Children. J Pediatr Gastroenterol Nutr. 2020 09; 71(3):354-360. View abstract
  2. Pediatric Collagenous Gastroenterocolitis Successfully Treated with Methotrexate. Case Rep Pediatr. 2020; 2020:1929581. View abstract
  3. Screening and Counseling for Alcohol Use in Adolescents With Chronic Medical Conditions in the Ambulatory Setting. J Adolesc Health. 2019 06; 64(6):804-806. View abstract
  4. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study. Lancet. 2019 04 27; 393(10182):1708-1720. View abstract
  5. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Nat Commun. 2019 01 03; 10(1):38. View abstract
  6. Effectiveness of oral iron supplementation in treatment of anemia associated with pediatric ulcerative colitis flare. Am J Hematol. 2018 12; 93(12):E404-E406. View abstract
  7. Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course. . 2018 10 10; 24(4):600-610.e4. View abstract
  8. Serologic Reactivity Reflects Clinical Expression of Ulcerative Colitis in Children. Inflamm Bowel Dis. 2018 05 18; 24(6):1335-1343. View abstract
  9. Commentary: Button Batteries in Fidget Spinners: Is It Time to Push the "Panic Button"? J Pediatr Gastroenterol Nutr. 2018 04; 66(4):557-558. View abstract
  10. Enhanced Contribution of HLA in Pediatric Onset Ulcerative Colitis. Inflamm Bowel Dis. 2018 03 19; 24(4):829-838. View abstract
  11. Protein-Losing Enteropathy in the Setting of Severe Iron Deficiency Anemia. J Investig Med High Impact Case Rep. 2018 Jan-Dec; 6:2324709618760078. View abstract
  12. Histologic Correlates of Clinical and Endoscopic Severity in Children Newly Diagnosed With Ulcerative Colitis. Am J Surg Pathol. 2017 Nov; 41(11):1491-1498. View abstract
  13. The Role of Environmental Factors in the Pathogenesis of Inflammatory Bowel Diseases: A Review. JAMA Pediatr. 2017 10 01; 171(10):999-1005. View abstract
  14. A randomized controlled trial of levodopa in patients with Angelman syndrome. . 2018 05; 176(5):1099-1107. View abstract
  15. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study. Lancet Gastroenterol Hepatol. 2017 12; 2(12):855-868. View abstract
  16. Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis. World J Gastroenterol. 2017 May 14; 23(18):3322-3329. View abstract
  17. Assessment of Fecal ASCA Measurement as a Biomarker of Crohn Disease in Pediatric Patients. J Pediatr Gastroenterol Nutr. 2017 02; 64(2):248-253. View abstract
  18. A Screening Tool for Assessing Alcohol Use Risk among Medically Vulnerable Youth. PLoS One. 2016; 11(5):e0156240. View abstract
  19. Health Care Maintenance in Adolescents with Inflammatory Bowel Disease. Adolesc Med State Art Rev. 2016; 27(1):177-92. View abstract
  20. Electrophysiological Studies into the Safety of the Anti-diarrheal Drug Clotrimazole during Oral Rehydration Therapy. PLoS Negl Trop Dis. 2015 Sep; 9(9):e0004098. View abstract
  21. Inflammatory bowel disease and neoplasia in children. Dig Dis. 2014; 32(4):455-62. View abstract
  22. NASPGHAN guidelines for training in pediatric gastroenterology. J Pediatr Gastroenterol Nutr. 2013 Jan; 56 Suppl 1:S1-8. View abstract
  23. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr. 2012 Jul; 55(1):93-108. View abstract
  24. Desquamative enteropathy and pyloric atresia without skin disease caused by a novel intracellular beta4 integrin mutation. J Pediatr Gastroenterol Nutr. 2008 Nov; 47(5):585-91. View abstract
  25. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008 Aug; 14(8):1091-6. View abstract
  26. Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib. J Inherit Metab Dis. 2008 Dec; 31 Suppl 3:505-9. View abstract
  27. Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib. Journal of Inherited Metababolic Disease. 2008; [Epub ahead of print] . View abstract
  28. Challenges and progress in pediatric inflammatory bowel disease. Curr Opin Gastroenterol. 2007 Jul; 23(4):406-12. View abstract
  29. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007 Apr; 44(4):414-22. View abstract
  30. Pancreatitis as the initial manifestation of stage IV neuroblastoma. J Pediatr Gastroenterol Nutr. 2007 Jan; 44(1):146-8. View abstract
  31. Why good pouches go bad. Inflamm Bowel Dis. 2007 Jan; 13(1):116-7. View abstract
  32. Pancreatitis as the intitial manifestation of Stage IV Neuroblastoma - A Case Report. Journal of Pediatric Gastroenterology Hepatology and Nutrition. 2007; 44(1):146-148. View abstract
  33. Current therapy of inflammatory bowel disease in children. Paediatr Drugs. 2006; 8(5):279-302. View abstract
  34. Current Therapy of Inflammatory Bowel Disease in Children . Pediatric Drugs. 2006; 8(5):279-302. View abstract
  35. Fecal ASCA Measurements in the Assessment of Pediatric Patients with Crohn’s Disease (CD) or Suspected Inflammatory Bowel Disease (IBD). American College of Gastroenterology (Las Vegas, NV). 2006. View abstract
  36. Severe colitis in children. J Pediatr Gastroenterol Nutr. 2005 Oct; 41(4):375-85. View abstract
  37. IBD in children: the more you look, the more you see.... Inflamm Bowel Dis. 2004 May; 10(3):327-8. View abstract
  38. Serial Fecal Lactoferrin Measurements are Useful in the Interval Assessment of Patients with Active and Inactive Inflammatory Bowel Disease. Digestive Disease Week - American Gastroenterological Association. 2004. View abstract
  39. Anti-inflammatory Activities Displayed by Triphenyl and Imidazole Containing Compounds. 2004. View abstract
  40. The Detection of Lactoferrin, ASCA and ANCA in Feces is useful for Assessing Pediatric IBD Patients. Digestive Disease Week - American Gastroenterological Association. 2004. View abstract
  41. Diarrhea – Pediatric. The Encyclopedia of Gastroenterology. 2004; 1:585-593. View abstract
  42. Diarrhea-associated HIV-1 APIs potentiate muscarinic activation of Cl- secretion by T84 cells via prolongation of cytosolic Ca2+ signaling. . 2004 May; 286(5):C998-C1008. View abstract
  43. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003 Jun; 98(6):1309-14. View abstract
  44. Enhancement of intracellular Ca Signaling and Chloride Transport by Nelfinavir and Other Aspartyl Protease inhibitors. 2003. View abstract
  45. Pouchitis: Evolution of a New Form of Inflammatory Bowel Disease. Diarrhea Digest. 2000. View abstract
  46. The antifungal antibiotic, clotrimazole, inhibits chloride secretion by human intestinal T84 cells via blockade of distinct basolateral K+ conductances. Demonstration of efficacy in intact rabbit colon and in an in vivo mouse model of cholera. J Clin Invest. 1997 Dec 15; 100(12):3111-20. View abstract
  47. Proteolytic activation of cholera toxin and Escherichia coli labile toxin by entry into host epithelial cells. Signal transduction by a protease-resistant toxin variant. J Biol Chem. 1997 Jun 13; 272(24):15562-8. View abstract
  48. Proteolytic Activation of cholera toxin by Eschericia coli labile toxin by entry into host epithelial cells: signal transduction by a proteolytic resistant toxin variant. J. Biol. Chem. 1997; 272:15562-15568. View abstract
  49. The antifungal antibiotic, clotrimazole, inhibits Cl- secretion by polarized monolayers of human colonic epithelial cells. J Clin Invest. 1996 Nov 01; 98(9):2066-75. View abstract
  50. Transcytosis of cholera toxin subunits across model human intestinal epithelia. Proc Natl Acad Sci U S A. 1995 Oct 24; 92(22):10094-8. View abstract
  51. Pulmonology. The Harriet Lane Handbook, K.B. Johnson e.d. 1994; 80-94. View abstract
  52. How families cope with diabetes in adolescence. An approach and case analyses. Pediatrician. 1988; 15(1-2):80-94. View abstract